LINC01503: A Drug Target / Disease Biomarker (G100506119)

Target Name: LINC01503

NCBI ID: G100506119

LINC01503

Other Name(s): Uncharacterized LOC100506119, transcript variant 1 | Long intergenic non-protein coding RNA 1503, transcript variant 1 | long intergenic non-protein coding RNA 1503 | Long intergenic non-protein coding RNA 1503, transcript variant 2 | LOC100506119 variant 1

LINC01503: A Drug Target / Disease Biomarker

LINC01503 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern have made it an attractive target for researchers to study, and recent studies have provided valuable insights into its functions and potential clinical applications.

LINC01503 is a long non-coding RNA molecule that has a length of approximately 200 nucleotides. It is expressed in a variety of tissues and cells in the body and is involved in the regulation of gene expression. It is highly expressed in the brain and has been identified as a potential drug target for several neurological and psychiatric diseases.

One of the key features of LINC01503 is its expression pattern. It is mainly expressed in the brain and has a strong expression in the default mode network (DMN), which is a set of brain regions involved in self-reflection and introspection. The DMN has been implicated in several mental health conditions, including depression, anxiety, and autism. Therefore, LINC01503 has been suggested as a potential therapeutic target for these diseases.

In addition to its expression pattern, LINC01503 has also been shown to play a role in several cellular processes in the brain, including cell survival, proliferation, and migration. It has been shown to promote the survival of neurons in neurodegenerative diseases and has been identified as a potential therapeutic target for Alzheimer's disease.

LINC01503 has also been shown to play a role in the regulation of inflammation and immune responses. It has been shown to regulate the production of pro-inflammatory cytokines and to promote the production of anti-inflammatory cytokines. These effects on inflammation and immune responses have implications for several diseases, including cancer and autoimmune disorders.

In conclusion, LINC01503 is a non-coding RNA molecule that has potential as a drug target and biomarker for several diseases. Its unique expression pattern and involvement in several cellular processes in the brain make it an attractive target for researchers to study and develop new therapeutic strategies. Further studies are needed to fully understand its functions and potential clinical applications.

Protein Name: Long Intergenic Non-protein Coding RNA 1503

The "LINC01503 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01503 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets